0

Close
 
Upcoming Allied Market Research
2023
Animal Insulin Market

Animal Insulin Market

by Product (Porcine Insulin, Bovine Insulin) and by Application (Human, Animals): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Healthcare
Report Code: A12463
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Animal Insulin Market

Request Now !

Animal Insulin Market Outlook 2030:

Animal insulin is a derivative of pigs and cows. Animal insulin was the primary sort of insulin to be regulated to control diabetes. Until the 1980s, creature insulin was the lone treatment for insulin subordinate diabetes. Animal insulin is available in three different types of actions and durations, short acting, intermediate acting, and long acting. Short acting insulin consists of porcine neutral and hypurin bovine neutral. Subsequently, intermediate acting consists of hypurin porcine isophane and hypurin bovine isophane. Lastly, long acting insulin consists of bovine lente and porcine lente. Short and intermediate insulins act quickly on the body while long acting insulin takes time to act post injecting. With the plethora of advantages, there are reports to suggest that animal insulin can at times cause lethargy, short term illness, behavioral changes, nausea, and vomiting.

COVID-19 Impact Analysis

The coronavirus pandemic has a huge impact on businesses and has already caused an unprecedented collapse of economic activities. The COVID-19 impact is straining the healthcare systems globally.

The COVID-19 cases are increasing due to direct or indirect contact between humans. There has been no evidence or confirmation that animals can spread COVID-19 to humans. The myth that animals can spread the virus to humans has increased the number of abandoned pets. Furthermore, COVID-19 has weakened the supply chain and has created shortage of animal health products such as nutritional feed as well as vaccines globally. The animal health industry has been impacted largely, as many manufacturers in the animal health industry are left with a significantly reduced workforce. In addition, implementation of stringent government policies such as restrictions of import of raw materials from China is expected to hamper the growth of the animal health market.

Healthcare facilities are stocking up the animal-related health products, considering the high demand. This is expected to further create financial strain on the market due to procurement inefficiencies and wasted speeding. Due to the pandemic situation, many hospitals and veterinary clinics are overstocking the products.

Top Impacting Factors

  • Insulin assists with denying amyloid stores from the amyloid polypeptide islet from creating amongst cats. Consequently, insulin is without a doubt the best solution for the control of diabetes in canine and cat thus prompting heavy growth across regions.
  • Animal insulin market is further anticipated to grow due to increase in diabetic patients and rise in examination exercises in the district and arrangement of different makers. The growing geriatric populace along with rising prevalence of diabetes among the populace and rising mindfulness among individuals with respect to the advantages of insulin contribute toward the animal insulin market growth.
  • A detriment of animal insulin is in the pinnacle movement time. The pinnacle movement period for short-acting insulin happens up to 3 to 4 hours in the wake of infusing, which can make timing of dinners comparable to infusions more troublesome than with human and especially simple insulin.

Key Market Trends

  • Insulin assists with denying amyloid stores from the amyloid polypeptide islet from creating amongst cats. Consequently, insulin is without a doubt the ideal solution for the control of diabetes.
  • Vetsulin/Caninsulin is porcine Lente insulin supported for use in the two cats and dogs. Vetsulin, ProZinc, and Caninsulin are authoritatively enrolled for veterinary use. Subordinate of ProZinc is protamine zinc insulin (PZI), which is endorsed to be utilized in cats and can be utilized in the administration of diabetic canines.
  • Insulin decreases blood glucose levels by expanding fringe utilization of glucose and by smothering the creation of hepatic glucose. Insulin treatment for diabetic cat and dog is the establishment of the consideration and numerous kinds of insulin were demonstrated to be productive.

Key Benefits of the Report

  • This study presents the analytical depiction of the animal insulin market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the animal insulin market share.
  • The current market is quantitatively analyzed to highlight the market scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Animal Insulin Market Report

  • Which are the leading players active in the animal insulin market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the animal insulin market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is animal insulin market?
  • What is the animal insulin market prediction in the future?
  • What are the current trends and predicted trends?

 Animal Insulin Market Report Highlights

Aspects Details
By Product
  • Porcine Insulin
  • Bovine Insulin
By Application
  • Human
  • Animals
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players BOEHRINGER INGELHEIM, Novo Nordisk, Ganlee, Tonghua Dongbao, Merck, MannKind Corporation, Eli Lilly, Wockhardt UK, Sanofi-Aventis, Zhuhai United Laboratories Co., Ltd.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: ANIMAL INSULIN MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Porcine Insulin

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Bovine Insulin

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: ANIMAL INSULIN MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Human

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Animals

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: ANIMAL INSULIN MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Animal Insulin Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Animal Insulin Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Animal Insulin Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Animal Insulin Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Animal Insulin Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Animal Insulin Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Animal Insulin Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Animal Insulin Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Animal Insulin Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Animal Insulin Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Animal Insulin Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Animal Insulin Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Animal Insulin Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Animal Insulin Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Animal Insulin Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Animal Insulin Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Animal Insulin Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Animal Insulin Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Animal Insulin Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Animal Insulin Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Animal Insulin Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Animal Insulin Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Animal Insulin Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Animal Insulin Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Animal Insulin Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Eli Lilly

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Novo Nordisk

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Sanofi-Aventis

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Tonghua Dongbao

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Ganlee

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Merck

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Wockhardt UK

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. MannKind Corporation

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. BOEHRINGER INGELHEIM

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Zhuhai United Laboratories Co., Ltd.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL INSULIN MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL ANIMAL INSULIN MARKET FOR PORCINE INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL ANIMAL INSULIN MARKET FOR BOVINE INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL ANIMAL INSULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL ANIMAL INSULIN MARKET FOR HUMAN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ANIMAL INSULIN MARKET FOR ANIMALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL ANIMAL INSULIN MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. NORTH AMERICA ANIMAL INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. NORTH AMERICA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 11. U.S. ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 12. U.S. ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 13. CANADA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 14. CANADA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. MEXICO ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 16. MEXICO ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. EUROPE ANIMAL INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. EUROPE ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. FRANCE ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 21. FRANCE ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. GERMANY ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. ITALY ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 25. ITALY ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. SPAIN ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. SPAIN ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. UK ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 29. UK ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. RUSSIA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. RUSSIA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. REST OF EUROPE ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. ASIA-PACIFIC ANIMAL INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. CHINA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 38. CHINA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. JAPAN ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. INDIA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. INDIA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. SOUTH KOREA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 44. SOUTH KOREA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. AUSTRALIA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. AUSTRALIA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. THAILAND ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. THAILAND ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. MALAYSIA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 50. MALAYSIA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. INDONESIA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 52. INDONESIA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. REST OF ASIA PACIFIC ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. LAMEA ANIMAL INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 56. LAMEA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. BRAZIL ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. BRAZIL ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. SOUTH AFRICA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. SAUDI ARABIA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 63. SAUDI ARABIA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. UAE ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. UAE ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. ARGENTINA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. ARGENTINA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. REST OF LAMEA ANIMAL INSULIN, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 69. REST OF LAMEA ANIMAL INSULIN, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. ELI LILLY: KEY EXECUTIVES
  • TABLE 71. ELI LILLY: COMPANY SNAPSHOT
  • TABLE 72. ELI LILLY: OPERATING SEGMENTS
  • TABLE 73. ELI LILLY: PRODUCT PORTFOLIO
  • TABLE 74. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 75. NOVO NORDISK: KEY EXECUTIVES
  • TABLE 76. NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 77. NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 78. NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 79. NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. SANOFI-AVENTIS: KEY EXECUTIVES
  • TABLE 81. SANOFI-AVENTIS: COMPANY SNAPSHOT
  • TABLE 82. SANOFI-AVENTIS: OPERATING SEGMENTS
  • TABLE 83. SANOFI-AVENTIS: PRODUCT PORTFOLIO
  • TABLE 84. SANOFI-AVENTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. TONGHUA DONGBAO: KEY EXECUTIVES
  • TABLE 86. TONGHUA DONGBAO: COMPANY SNAPSHOT
  • TABLE 87. TONGHUA DONGBAO: OPERATING SEGMENTS
  • TABLE 88. TONGHUA DONGBAO: PRODUCT PORTFOLIO
  • TABLE 89. TONGHUA DONGBAO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. GANLEE: KEY EXECUTIVES
  • TABLE 91. GANLEE: COMPANY SNAPSHOT
  • TABLE 92. GANLEE: OPERATING SEGMENTS
  • TABLE 93. GANLEE: PRODUCT PORTFOLIO
  • TABLE 94. GANLEE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. MERCK: KEY EXECUTIVES
  • TABLE 96. MERCK: COMPANY SNAPSHOT
  • TABLE 97. MERCK: OPERATING SEGMENTS
  • TABLE 98. MERCK: PRODUCT PORTFOLIO
  • TABLE 99. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. WOCKHARDT UK: KEY EXECUTIVES
  • TABLE 101. WOCKHARDT UK: COMPANY SNAPSHOT
  • TABLE 102. WOCKHARDT UK: OPERATING SEGMENTS
  • TABLE 103. WOCKHARDT UK: PRODUCT PORTFOLIO
  • TABLE 104. WOCKHARDT UK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. MANNKIND CORPORATION: KEY EXECUTIVES
  • TABLE 106. MANNKIND CORPORATION: COMPANY SNAPSHOT
  • TABLE 107. MANNKIND CORPORATION: OPERATING SEGMENTS
  • TABLE 108. MANNKIND CORPORATION: PRODUCT PORTFOLIO
  • TABLE 109. MANNKIND CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. BOEHRINGER INGELHEIM: KEY EXECUTIVES
  • TABLE 111. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 112. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 113. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 114. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. ZHUHAI UNITED LABORATORIES CO., LTD.: KEY EXECUTIVES
  • TABLE 116. ZHUHAI UNITED LABORATORIES CO., LTD.: COMPANY SNAPSHOT
  • TABLE 117. ZHUHAI UNITED LABORATORIES CO., LTD.: OPERATING SEGMENTS
  • TABLE 118. ZHUHAI UNITED LABORATORIES CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 119. ZHUHAI UNITED LABORATORIES CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL INSULIN MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ANIMAL INSULIN MARKET
  • FIGURE 3. SEGMENTATION ANIMAL INSULIN MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ANIMAL INSULIN MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALANIMAL INSULIN MARKET
  • FIGURE 11. ANIMAL INSULIN MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. ANIMAL INSULIN MARKET FOR PORCINE INSULIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ANIMAL INSULIN MARKET FOR BOVINE INSULIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ANIMAL INSULIN MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. ANIMAL INSULIN MARKET FOR HUMAN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. ANIMAL INSULIN MARKET FOR ANIMALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 21. COMPETITIVE DASHBOARD
  • FIGURE 22. COMPETITIVE HEATMAP: ANIMAL INSULIN MARKET
  • FIGURE 23. Top player positioning, 2022
  • FIGURE 24. ELI LILLY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 25. ELI LILLY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 26. ELI LILLY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 27. NOVO NORDISK: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 28. NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 29. NOVO NORDISK: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 30. SANOFI-AVENTIS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. SANOFI-AVENTIS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. SANOFI-AVENTIS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. TONGHUA DONGBAO: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. TONGHUA DONGBAO: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. TONGHUA DONGBAO: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. GANLEE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. GANLEE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. GANLEE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. MERCK: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. MERCK: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. MERCK: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. WOCKHARDT UK: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. WOCKHARDT UK: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. WOCKHARDT UK: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. MANNKIND CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. MANNKIND CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. MANNKIND CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. BOEHRINGER INGELHEIM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. ZHUHAI UNITED LABORATORIES CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. ZHUHAI UNITED LABORATORIES CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. ZHUHAI UNITED LABORATORIES CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Animal Insulin Market

Start reading.
This Report and over 68,113+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers